natgillin/translations-raw huggingface dataset:
Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly. 
Ker je na splošno pojavnost okužb v tej populaciji večja, je pri zdravljenju starostnikov potrebna previdnost.
Radiographic Response 
Radiografski odziv
Monoclonal antibodies are proteins that recognise and bind specifically to certain proteins in the body. 
Monoklonska protitelesa so beljakovine, ki v telesu prepoznajo točno določene beljakovine in se nanje vežejo.
The syringe is fitted with a passive safety guard. 
Brizga je opremljena s pasivnim varnostnim pripomočkom.
• Itching (‘pruritus') 
• srbenje (‘pruritus')
If you have a serious allergic reaction, your doctor may decide that you should not use Stelara again. 
Če imate hudo alergijsko reakcijo, se vaš zdravnik lahko odloči, da zdravila Stelara ne smete več uporabljati.
UNIFI-I included 961 patients. 
V študijo UNIFI-I je bilo vključenih 961 bolnikov.
There are no adequate data from the use of ustekinumab in pregnant women. 
Ni zadostnih podatkov o uporabi ustekinumaba pri nosečnicah.
After this, dosing every 12 weeks is recommended. 
Nato se priporoča odmerjanje na vsakih 12 tednov.
If not used immediately, in-use storage times and conditions are the responsibility of user. 
Če zdravilo ne bo porabljeno takoj, je za čas in pogoje shranjevanja odgovoren uporabnik.
No specific studies have been conducted in elderly patients. 
Pri starejših niso bile opravljene specifične študije.
Patients in these studies had a diagnosis of PsA for at least 6 months. 
Bolniki v teh preskušanjih so imeli PsA diagnosticiran že najmanj 6 mesecev.
Signs include: 
Znaki so:
• After the expiry date which is stated on the label and the carton after ‘EXP'. 
• po datumu izteka roka uporabnosti, ki je naveden na viali in na škatli poleg oznake ‘EXP'
Most were considered to be mild and did not necessitate discontinuation of study treatment. 
Večina neželenih učinkov je bila zmernih in zaradi njih ni bila potrebna prekinitev zdravljenja v študiji.
Efficacy data were collected and analyzed through week 8 for both studies. 
V obeh študijah so podatke o učinkovitosti zbirali in analizirali v 8. tednu.
If necessary, the diluted infusion solution may be stored at room temperature. 
Če je potrebno, se lahko razredčena raztopina za infundiranje shranjuje pri sobni temperaturi.
Approximately 50% of patients continued on stable doses of MTX (≤ 25 mg/week). 
Približno 50% bolnikov je zdravljenje nadaljevalo s stalnimi odmerki MTX(≤ 25 mg/teden).
* See section 4.4, Systemic and respiratory hypersensitivity reactions. 
* glejte poglavje 4.4 Sistemske in dihalne preobčutljivostne reakcije
Before you use Stelara tell your doctor: 
Pred začetkom uporabe zdravila Stelara, svojemu zdravniku povejte:
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. 
Zaradi pomanjkanja študij kompatibilnosti, zdravila ne smete mešati z drugimi zdravili.
• If you know, or think that it may have been exposed to extreme temperatures (such as accidentally frozen or heated). 
• če veste ali mislite, da je bilo zdravilo morda izpostavljeno skrajnim temperaturam (na primer če je po nesreči zmrznilo ali se segrelo);
In Crohn's disease, if therapy is interrupted, resumption of treatment with subcutaneous dosing every 8 weeks is safe and effective. 
Če pri Crohnovi bolezni pride do prekinitve zdravljenja, je ponovna uvedba zdravljenja s subkutanim odmerjanjem na vsakih 8 tednov varna in učinkovita.
• Store in a refrigerator (2°C-8°C). 
• Shranjujte v hladilniku (2°C-8°C).
Do not use the medicine if it has been shaken strongly. 
Zdravila torej ne smete uporabiti, če je bilo močno stresano.
The first study was in 110 patients from 12 to 17 years of age treated for up to 60 weeks and the second study was in 44 patients from 6 to 11 years of age treated for up to 56 weeks. 
V prvo študijo so vključili 110 bolnikov, starih od 12 do 17 let, zdravljenih do največ 60 tednov, v drugo pa 44 bolnikov, starih od 6 do 11 let in zdravljenih do največ 56 tednov.
Biotransformation The exact metabolic pathway for ustekinumab is unknown. 
Biotransformacija Natančna pot presnove ustekinumaba ni znana.
Concomitant use of immunomodulators did not have a significant impact on ustekinumab disposition. 
Sočasna uporaba imunomodulatorjev ni pomembno vplivala na razpoložljivost ustekinumaba.
Improvement in health-related quality of life was generally maintained during the extension through week 92. 
Izboljšanje v z zdravjem povezano kakovostjo življenja se je med nadaljevanjem v glavnem ohranilo do 92. tedna.
Your doctor will decide when you should receive your next dose. 
Zdravnik se bo odločil kdaj boste prejeli naslednji odmerek.
Other medicines, vaccines and Stelara 
Druga zdravila, cepiva in zdravilo Stelara
Immunomodulators and/or corticosteroids may be continued during treatment with STELARA. 
Zdravljenje z imunomodulatorji in/ali kortikosteroidi se med zdravljenjem z zdravilom STELARA lahko nadaljuje.
• warm, red and painful skin, or a painful skin rash with blisters 
• toplo, rdečo in bolečo kožo ali boleč kožni izpuščaj v obliki mehurčkov
• feeling tired or short of breath; cough which will not go away 
• občutek utrujenosti ali težkega dihanja, kašelj, ki ne mine
The improvement was sustained through week 28. 
Izboljšanje je bilo dokazano tudi v 28. tednu.
Clinically important, active infection (e.g. active tuberculosis; see section 4.4). 
Klinično pomembna, aktivna okužba (npr. aktivna tuberkuloza; glejte poglavje 4.4).
• Improve your physical function. 
• za izboljšanje telesne zmogljivosti,
Clinical Remission, week 8 
Klinična remisija, 8. teden
Traceability: 
Sledljivost:
Anaphylaxis and angioedema have occurred. 
Prišlo je do pojava anafilaksije in angioedema.
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP. 
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženemv modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih posodobitvah RMP.
The ratio of patients with basal versus squamous cell skin cancers (3:1) is comparable with the ratio expected in the general population (see section 4.4). 
Delež bolnikov z bazalnoceličnim karcinomom proti ploščatoceličnim karcinomom kože (3:1) je primerljiv pričakovanemu deležu v splošni populaciji (glejte poglavje 4.4).
Adolescent patients (12-17 years) 
Mladostniki (stari 12-17 let)
See ‘Look out for serious side effects' in section 4 for the signs of an allergic reaction. 
Glejte 'Bodite pozorni na resne neželene učinke' v poglavju 4 za znake in simptome alergijske reakcije.
In Study 1 previous treatment with anti-tumour necrosis factor (TNF)α agent was not allowed. 
V 1. študiji predhodno zdravljenje z zaviralcem tumorske nekroze (TNF-anti-tumour necrosis factor) α ni bilo dovoljeno.
Adults aged 18 years or older 
Odrasli, stari 18 let in več
This appearance is not unusual for proteinaceous solutions. 
Ta videz ni nenavaden za vodne raztopine beljakovin.
The proportion of patients with a PGA score of cleared (0) or minimal (1) at week 12 was 77.3%. 
Delež bolnikov z oceno PGA čisto (0) ali minimalno (1) v 12. tednu je bil 77,3%.
Tell your doctor if you have any kind of infection that will not go away or keeps coming back. 
Zdravnika obvestite, če imate okužbo, ki ne mine ali ki se ponavlja.
• Do not rub the skin at the injection site. 
• Ne drgnite kože na mestu injiciranja.
The most frequently observed malignancies, other than non-melanoma skin cancer, were prostate, colorectal, melanoma and breast cancers. 
Najpogosteje opaženi malignomi, razen nemelanomskega kožnega raka, so bili rak prostate, kolorektalni rak, melanom in rak dojk.
• If you have ever had an allergic reaction to latex or Stelara injection - the container of this medicinal product contains latex rubber, which may cause severe allergic reactions in people who are sensitive to latex. 
• če ste kdaj imeli alergijsko reakcijo na latex ali injekcijo zdravila Stelara - vsebnik tega zdravila vsebuje pokrovček iz lateksa, ki lahko povzroči hude alergijske reakcije pri ljudeh, ki so nanj občutljivi.
• If you have or have had a recent infection. 
• če imate ali ste nedavno imeli okužbo.
In the population pharmacokinetic analysis, there were no indications of an effect of tobacco or alcohol on the pharmacokinetics of ustekinumab. 
V analizi populacijske farmakokinetike ni bilo znakov vpliva tobaka ali alkohola na farmakokinetiko ustekinumaba.
• A change in psoriasis with redness and new tiny, yellow or white skin blisters, sometimes accompanied by fever (pustular psoriasis) 
• spremembe v psoriazi z rdečino in novimi, rumenimi ali belimi mehurji na koži, ki jih včasih spremlja vročina (pustularna psoriaza)
CDLQI of 0 or 1 
CDLQI 0 ali 1
Ustekinumab may have the potential to increase the risk of infections and reactivate latent infections. 
Ustekinumab lahko poveča tveganje za nastanek okužb in vodi do reaktivacije latentnih okužb.
Similar symptoms sometimes develop as a natural change in the type of psoriasis symptoms (erythrodermic psoriasis) 
Podobni simptomi se včasih razvijejo kot spontana sprememba oblike psoriatičnih simptomov (eritrodermična psoriaza).
Immunosuppressants like ustekinumab have the potential to increase the risk of malignancy. 
Imunosupresivna zdravila, kot je ustekinumab, lahko povečajo tveganje za nastanek malignomov.
• the solution is not frozen. 
• da ni zamrznjena.
The solution may contain a few small translucent or white particles of protein. 
Raztopina lahko vsebuje nekaj majhnih, prosojnih ali belih beljakovinskih delcev.
The adverse reactions are classified by System Organ Class and frequency, using the following convention: Very common (≥ 1/10), Common (≥ 1/100 to < 1/10), Uncommon (≥ 1/1,000 to < 1/100), Rare (≥ 1/10,000 to < 1/1,000), Very rare (< 1/10,000), not known (cannot be estimated from the available data). 
Neželeni učinki so razvrščeni po organskih sistemih in po pogostnosti z upoštevanjem naslednjega dogovora: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Improvement has been reported after discontinuation of ustekinumab and also, in some cases, administration of corticosteroids. 
O izboljšanju so poročali po prekinitvi zdravljenja in v nekaterih primerih po odmerjanju kortikosteroidov.
Stelara may make you less able to fight infections, and some infections could become serious. 
Zdravilo Stelara lahko zmanjša vašo sposobnost za boj proti okužbam in nekatere okužbe lahko postanejo resne.
This should be taken into consideration for patients on a controlled sodium diet (see section 6.6). 
To je treba upoštevati pri bolnikih na dieti z nadzorovanim vnosom natrija (glejte poglavje 6.6).
The right dose for you will depend on your body weight at the time each dose is given. 
Pravi odmerek za vas je odvisen od vaše telesne mase v času odmerka.
Fertility The effect of ustekinumab on human fertility has not been evaluated (see section 5.3). 
Plodnost Vpliva ustekinumaba na plodnost pri ljudeh niso ovrednotili (glejte poglavje 5.3).
• If you are taking, have recently taken or might take any other medicines. 
• če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo,
Similar results were obtained from a confirmatory population pharmacokinetic analysis using data from patients with psoriatic arthritis. 
Podobne rezultate je pokazala potrditvena populacijska farmakokinetična analiza, kjer so uporabili podatke bolnikov s psoriatičnim artritisom.
Elderly (≥ 65 years) No dose adjustment is needed for elderly patients (see section 4.4). 
Starejši (≥ 65 let) Pri starejših ni potrebno prilagajati odmerkov (glejte poglavje 4.4).
Prepare the injection site 
Pripravite mesto injiciranja
Uncommon: Depression 
Občasni: depresija
ACR 20, 50 and 70 responses continued to improve or were maintained through week 52 (PsA Study 1 and 2) and week 100 (PsA Study 1). 
Odzivi ACR 20, 50 in 70 so se izboljševali ali se ohranili do 52. tedna (1. in 2. študija PsA) in do 100. tedna (1. študija PsA).
Before live viral or live bacterial vaccination, treatment with STELARA should be withheld for at least 15 weeks after the last dose and can be resumed at least 2 weeks after vaccination. 
Pred cepljenjem z živimi virusnimi ali živimi bakterijskimi cepivi je treba zdravljenje z zdravilom STELARA odložiti za najmanj 15 tednov po zadnjem odmerku in ga lahko ponovno uvedete šele najmanj 2 tedna po cepljenju.
• If you ever had an allergic reaction to Stelara. 
• če ste imeli kdaj alergijsko reakcijo na zdravilo Stelara.
Volume of injection (mL) 
Volumen raztopine (ml)
STELARA does not contain preservatives; therefore any unused medicinal product remaining in the vial and the syringe should not be used. 
Zdravilo STELARA ne vsebuje konzervansov, zato neporabljenega zdravila, ki ostane v viali ali brizgi, ne smete uporabiti.
Patients with PASI ≥ 12, PGA ≥ 3 and BSA involvement of at least 10%, who were candidates for systemic therapy or phototherapy, were eligible for the study. 
Bolniki, ki so imeli PASI ≥ 12, PGA ≥ 3 in BSA najmanj 10% ter so bili kandidati za sistemsko terapijo ali fototerapijo, so bili primerni za vključitev v študijo.
Common: Pruritus 
Pogosti: pruritus
If you do not respond well enough to these medicines, you may be given Stelara to: 
Če se nanje ne boste zadostno odzvali, boste prejeli zdravilo Stelara za:
• Do not touch the needle guard activation clips (as indicated by asterisks * in Figure 1) to prevent prematurely covering the needle with the needle guard. 
• Ne dotikajte se aktivacijskih nastavkov ščitnika igle (ki sta označena z zvezdico na Sliki 1), da ne bi prišlo do prezgodnjega prekritja igle s ščitnikom igle.
It is not known if ustekinumab is absorbed systemically after ingestion. 
Ni znano, ali se ustekinumab sistemsko absorbira po zaužitju.
Prescribers should consult the Summary of Product Characteristics for the specific vaccine for additional information and guidance on concomitant use of immunosuppressive agents post-vaccination. 
Zdravniki morajo prebrati povzetek glavnih značilnosti posameznega cepiva, v katerih bodo našli tudi dodatne informacije in smernice o sočasni uporabi imunosupresivnih zdravil po cepljenju.
After the injection: 
Po injiciranju:
This will let the liquid come to a comfortable temperature for injection (room temperature). 
Tako se bo tekočina segrela na temperaturo, ki je primerna za injiciranje (sobna temperatura).
• Stelara 130 mg concentrate for solution for infusion is given in a hospital or clinic and patients should not need to store or handle it. 
• Zdravilo Stelara 130 mg koncentrat za raztopino za infundiranje boste prejeli v bolnišnici ali kliniki in vam ga ne bo treba shranjevati ali z njim rokovati.
A pre-specified integrated analysis combining data from 927 subjects in both PsA Study 1 and 2 was performed. 
Izvedena je bila vnaprej določena analiza, sestavljena iz podatkov 927 bolnikov iz 1. in 2. študije PsA.
Choose and prepare the injection site: 
Izberite in pripravite mesto injiciranja:
• Do not remove the stopper 
• Zamaška ne odstranite.
The results of an in vitro study do not suggest the need for dose adjustments in patients who are receiving concomitant CYP450 substrates (see section 5.2). 
Rezultati študij in vitro ne kažejo potrebe po prilagajanju odmerka pri bolnikih, ki sočasno prejemajo substrate encima CYP450 (glejte poglavje 5.2).
The incidence of malignancies reported in ustekinumab-treated patients was comparable to the incidence expected in the general population (standardised incidence ratio = 0.93 [95% confidence interval: 0.71, 1.20], adjusted for age, gender and race). 
Pogostnost malignomov, poročanih pri bolnikih, zdravljenih z ustekinumabom, je bila podobna pričakovani pogostnosti v splošni populaciji (standardiziran količnik incidence = 0,93 [95% interval zaupanja: 0,71; 1,20], prilagojen za starost, spol in raso).
• For instructions on how to inject Stelara, see ‘Instructions for administration' at the end of this leaflet. 
• Za dodatne informacije o injiciranju zdravila Stelara glejte poglavje ‘Navodilo za injiciranje zdravila' na koncu tega navodila.
Children weighing less than 60 kg need a dose lower than 45 mg. Make sure you know the proper amount (volume) to remove from the vial and type of syringe needed for dosing. 
Odmerek pri otrocih, ki tehtajo manj kot 60 kg, je manjši od 45 mg. Preverite, da imate brizgo ustrezne velikosti, s katero boste iz viale izvlekli potrebno količino (volumen) zdravila za odmerjanje.
Before administration, STELARA should be allowed to reach room temperature (approximately half an hour). 
Pred dajanjem mora zdravilo STELARA doseči sobno temperaturo (približno pol ure na sobni temperaturi).
From a microbiological point of view, unless the method of dilution precludes the risk of microbial contamination, the product should be used immediately. 
Z mikrobiološkega stališča je treba raztopino uporabiti takoj, razen če postopek redčenja izključuje tveganje za kontaminacijo z mikrobi.
Use a new needle and syringe for each injection. 
Za vsako injekcijo morate uporabiti novo iglo in brizgo.
Patients or their caregivers should be instructed to inject the prescribed amount of STELARA according to the directions provided in the package leaflet. 
Bolnikom ali njihovim skrbnikom naročite, naj si injicirajo predpisano količino zdravila STELARA v skladu z navodilom za uporabo.
A beneficial effect was also observed in induction in patients who failed at least one prior TNFα antagonist therapy and vedolizumab, however the number of patients in this subgroup was too small to draw definitive conclusions about the beneficial effect in this group during maintenance. 
Ugoden učinek so opazili tudi pri indukcijskem zdravljenju bolnikov z neuspešnim predhodnim zdravljenjem z najmanj enim od zaviralcev TNFα in vedolizumabom, vendar je bilo število bolnikov v tej podskupini premajhno, da bi lahko sprejeli dokončne zaključke o ugodnih učinkih v času vzdrževalnega zdravljenja pri tej skupini bolnikov.
Dosing frequency adjustment 
Prilagajanje pogostnosti odmerjanja
Stelara belongs to a group of medicines called ‘immunosuppressants'. 
Zdravilo Stelara sodi v skupino zdravil, ki jih imenujemo ‘imunosupresivi'.
Stelara can cause serious side effects, including allergic reactions and infections. 
Zdravilo Stelara lahko povzroči resne neželene učinke, vključno z alergijskimi reakcijami in okužbami.
To calculate the volume of injection (mL) for patients < 60 kg, use the following formula: body weight (kg) x 0.0083 (mL/kg) or see Table 2. 
Za izračun volumna raztopine (ml) pri bolnikih s telesno maso < 60 kg uporabite naslednjo formulo: telesna masa (kg) x 0,0083 (ml/kg) ali glejte Preglednico 2.
Stelara will reduce the inflammation and other signs of the disease. 
Zdravilo Stelara zmanjša vnetje in druge bolezenske znake.
• If you have or have had a recent infection or if you have any abnormal skin openings (fistulae). 
• če imate ali ste nedavno imeli okužbo ali nenormalne odprtine na koži (fistule).
It is recommended that live viral or live bacterial vaccines (such as Bacillus of Calmette and Guérin (BCG)) should not be given concurrently with STELARA. 
Priporočljivo je, da živih virusnih ali živih bakterijskih cepiv (na primer cepiva z Bacillusom Calmette-Guérin - BCG) ne dajete v času zdravljenja z zdravilom STELARA.
Similar disease severity was also seen in Psoriasis Study 3. 
Značilnosti bolezni so bile podobne tudi v 3. študiji psoriaze.
In Psoriasis Study 1 maintenance of PASI 75 was significantly superior with continuous treatment compared with treatment withdrawal (p < 0.001). 
V 1. študiji psoriaze je bilo ohranjanje PASI 75 bistveno boljše pri neprekinjenem zdravljenju kot pri prenehanju zdravljenja (p < 0,001).
• Put the vial on a flat surface. 
• Vialo položite na ravno površino.
Check the number of vials and prepare the materials: 
Preverite število vial in si vse pripravite:
Psoriasis Study 2 (PHOENIX 2) evaluated 1,230 patients. 
V 2. študiji psoriaze (PHOENIX 2) so ovrednotili 1.230 bolnikov.
Efficacy results presented for UNIFI-I and UNIFI-M were based on central review of endoscopies. 
Prikazani rezultati za oceno učinkovitosti iz študij UNIFI-I in UNIFI-M temeljijo na ocenah centralnega pregleda endoskopij.
Take the vial(s) out of the refrigerator. 
Vialo (viali) vzemite iz hladilnika.
Psoriasis Study 1 (PHOENIX 1) evaluated 766 patients. 
V 1. študiji psoriaze (PHOENIX 1) so ovrednotili podatke za 766 bolnikov.
• If you are allergic to ustekinumab or any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični na ustekinumab ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
All patients, in particular those greater than 60 years of age, patients with a medical history of prolonged immunosuppressant therapy or those with a history of PUVA treatment, should be monitored for the appearance of non-melanoma skin cancer (see section 4.8). 
Vse bolnike, še posebno pa bolnike, starejše od 60 let, bolnike, ki so dolgo časa prejemali imunosupresive ali tiste, ki so prejemali zdravljenje s PUVA, je treba spremljati zaradi možnosti pojava nemelanomskega kožnega raka (glejte poglavje 4.8).
It is unknown whether ustekinumab is excreted in human breast milk. 
Ni znano, ali se ustekinumab izloča v materino mleko pri človeku.
Treatment of latent tuberculosis infection should be initiated prior to administering STELARA. 
Zdravljenje latentne tuberkulozne okužbe je treba začeti še pred uporabo zdravila STELARA.
• Good places for the injection are the upper thigh or around the belly (abdomen) at least 5 cm away from the navel (belly button) 
• Primerna mesta za injiciranje zdravila so zgornji del stegna ali trebuh (abdomen), in sicer najmanj 5 cm stran od popka.
Push it slowly and evenly, keeping the skin gently pinched 
Bat potiskajte počasi in enakomerno ter pri tem nežno stiskajte kožo v gubo.
In case of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately. 
V primeru prevelikega odmerjanja je priporočljivo, da bolnika spremljate, da bi lahko ugotovili morebitne znake in simptome neželenih učinkov ter jim takoj uvedli ustrezno simptomatsko zdravljenje.
Week 12 2 doses (week 0 and week 4) 
12. teden 2 odmerka (v tednu 0 in 4)
The solution is clear to slightly opalescent, colourless to light yellow and may contain a few small translucent or white particles of protein. 
Raztopina je bistra do rahlo opalescentna in brezbarvna do svetlo rumena ter lahko vsebuje nekaj majhnih prosojnih ali belih beljakovinskih delcev.
Your doctor may decide that you should not use Stelara until the infection goes away. 
Zdravnik se lahko odloči, da zdravila Stelara ne smete jemati, dokler traja okužba.
If you forget to use Stelara 
Če ste pozabili uporabiti zdravilo Stelara
• Do not mix Stelara with other liquids for injection 
• Zdravila Stelara ne smete mešati z drugimi tekočinami za injiciranje.
Your body weight 
Vaša telesna masa
• the solution in the pre-filled syringe is not frozen. 
• da raztopina v napolnjeni injekcijski brizgi ni zmrznjena.
Impact of weight on pharmacokinetics 
Vpliv telesne mase na farmakokinetiko
These may be signs of infections such as chest infections, or skin infections or shingles that could have serious complications. 
To so lahko znaki okužbe spodnjih dihal, okužbe kože ali pasavec, zaradi katerih lahko pride do resnih zapletov.
• If possible, do not use areas of skin that show signs of psoriasis 
• Če je mogoče, zdravila ne injicirajte na mesta, ki kažejo znake psoriaze.
• Slowly take your thumb off the plunger head to allow the empty syringe to move up until the entire needle is covered by the needle guard, as shown by Figure 7: 
• Počasi umaknite palec z glave bata, da se prazna brizga pomakne navzgor, dokler ni cela igla prekrita s ščitnikom, kot je prikazano na Sliki 7: